Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | P2RX3 | P56373 | 10/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.40 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | CCR9 | P51686 | 2/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1483423 | 0.97 | NR1H4 (0.42) | KDM4EP2RX3NR1H4SCN7ASCN5A | |
| SCHEMBL1482713 | 0.91 | NR1H4 (0.46) | KDM4EP2RX3NR1H4TBXA2R | |
| SCHEMBL1482665 | 0.89 | KDM4E (0.47) | KDM4EP2RX3NR1H4CCR9DRD2 | |
| SCHEMBL1482644 | 0.89 | NR1H4 (0.43) | P2RX3NR1H4SCN7ASCN5ADRD2 | |
| SCHEMBL1482284 | 0.88 | NR1H4 (0.49) | KDM4EP2RX3NR1H4TBXA2R | |
| SCHEMBL1482749 | 0.87 | P2RX3 (0.43) | P2RX3NR1H4 | |
| SCHEMBL1482376 | 0.85 | DRD2 (0.47) | P2RX3NR1H4DRD2TBXA2R | |
| SCHEMBL1482913 | 0.85 | KDM4E (0.48) | KDM4EP2RX3NR1H4CCR9RPS6KA3 | |
| SCHEMBL1483153 | 0.85 | KDM4E (0.45) | KDM4EP2RX3CCR9DRD2TBXA2R | |
| SCHEMBL1482358 | 0.85 | FFAR4 (0.41) | KDM4EP2RX3CCR9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309581-B2 | Benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077273-A1 | NEW BENZIMIDAZOLE DERIVATIVES | BRI3BP, CYP3A4, RB1 | KDM4E 1791/4885P2RX3 557/4885NR1H4 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.